Atripla (Efavirenz/Tenofovir/FTC)
| Brand Name: |
Atripla |
| Generic Name: |
Efavirenz/ tenofovir/ emtricitabine, EFV/TDF/FTC |
| Adult Single Dose: |
One tablet containing 600 mg efavirenz, 300 mg tenofovir and 200 mg FTC |
| Food & Liquid Restrictions: |
Take on an empty stomach |
| Drug Class: |
1 NNRTI + 2 NRTIs |
The Basics
News
- Switching From Atripla to Complera (January/February 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Complera and Atripla News (January/February 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Gilead Raises Prices of HIV Drugs, AHF Speaks Out Against Price Hike (April 4, 2011)
In Bloomberg Businessweek
- Atripla's Co-Pay Program Now Saves More Money (September/October 2010)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- The Once and Future King: What Will Replace Atripla Atop the First-Line HIV Treatment Realm? (Feb. 19, 2010; 3:39 p.m. Pacific Time)
A blog entry from CROI 2010 by Gerald Pierone Jr., M.D.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Atripla Label Update Reflects New Efficacy, Safety and Resistance Data in Treatment Experienced Patients (January 7, 2010)
From U.S. Food and Drug Administration
- Australia: New HIV Drug Added to Taxpayer-Subsidized List (January 4, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Approval for Once-A-Day HIV Pill (December 17, 2007)
In BBC News Online, from BBC News
- FDA Approves Gilead, Bristol-Myers Squibb Once-a-Day Combination Antiretroviral Pill (July 13, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Single-Pill, Once-Daily HIV Drug Regimen Submitted for FDA Approval (April 28, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce (January 9, 2006)
Filing of a new drug application is expected in the second quarter of 2006.
To read PDF, click here.
From Bristol-Myers Squibb Company and Gilead Sciences, Inc.
- Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Research
- Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study (March 7, 2012)
Quad currently under review for marketing approval by U.S. and European regulatory agencies.
From Gilead Sciences, Inc.
On TheBodyPRO.com
- Switch to HIV Combo Pill May Improve Lipids (September 15, 2010)
From MedPage Today
- Lipids Drop After Switch From ABC/3TC/Efavirenz to Atripla (September 15, 2010)
From National AIDS Treatment Advocacy Project
- "Quad" Tablet vs. Atripla; GS 9350 (Cobicistat) vs. Ritonavir (March 8, 2010)
Part of a CROI 2010 wrap-up discussion with Joel Gallant, M.D., M.P.H.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- QUAD Four-in-One Pill as Strong as Atripla, but a Kidney Concern Arises (February 18, 2010)
From National AIDS Treatment Advocacy Project
- Study Shows People Can Safely Switch to Atripla (December 2008)
To read PDF, click here.
From Project Inform
On TheBodyPRO.com
|
|
Advertisement
|
Email
Glossary
